Zobrazeno 1 - 3
of 3
pro vyhledávání: '"D. P. Balandin"'
Autor:
N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. V. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 5, Pp 668-673 (2021)
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research cent
Externí odkaz:
https://doaj.org/article/fda3bc3bcec0409e89ef6af250af93a3
Autor:
N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. S. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 2, Pp 193-199 (2021)
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research cent
Externí odkaz:
https://doaj.org/article/0f377f87549f4a628c7889891fa7039f
Publikováno v:
2022 International Siberian Conference on Control and Communications (SIBCON).